Eli Lilly will invest more than $1.2bn into its manufacturing site in Puerto Rico, as the drugmaker looks to assemble a ...

Eli Lilly (NYSE: LLY) delivered a commanding third quarter, posting earnings and revenue that significantly exceeded ...

Eli Lilly's $1.2 billion investment in Puerto Rico aims to enhance manufacturing capabilities and integrate advanced technologies for oral solid medicines. The investment is part of Lilly's broader ...

The investment, which will expand Eli Lilly’s existing campus in Puerto Rico, is slated to create 100 new jobs, on top of ...

The Carolina campus modernization will create 1,100 jobs boost production capacity, and strengthen the island’s role in U.S.

Reports Q3 revenue $17.6B, consensus $16.07B. “Lilly delivered another strong quarter, with 54% revenue growth year-over-year driven by continued ...

Lilly predicts it will achieve an adjusted profit of between $23.00 and $23.70 per share this year, an increase on its ...

Eli Lilly shares surged after strong third-quarter results and a raised annual forecast, powered by booming demand for its ...

A particularly noteworthy achievement emerged this quarter: Eli Lilly's tirzepatide franchise overtook Merck's cancer immunotherapy Keytruda to become the world's highest-grossing medication. This ...

Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound. Q3 2025 EPS increased by $5.14 to $6.21 on a reported ...

Both sales figures came in well ahead of analyst expectations and will heap pressure on Lilly's main rival in the GLP-1 ...

Also looking to the future, Eli Lilly Chairman and CEO David A. Ricks stated, “We advanced orforglipron through four ...